Pathalys Pharma, a Research Triangle Park, NC biopharmaceutical startup developing kidney disease medicines, raised $105M in Series B funding.
Leading the round was TCGX, backed by founding investors of Pathalys, Catalys Pacific and DaVita Venture Group, as well as additional investors Marshall Wace, Samsara BioCapital, JP Morgan Life Sciences Private Capital, KB Investment, and JPS Growth Investment Limited Partnership.
The company plans to use the money to expedite preapproval commercialization preparations, complete the two ongoing upacicalcet clinical trials, and file an NDA with the US Food and Drug Administration (FDA).
A late-stage clinical biopharmaceutical startup, Pathalys Pharma is dedicated to creating a variety of cutting-edge treatments that fill gaps in the treatment of end-stage kidney disease.
Upacicalcet, a new calcimimetic that may enhance the therapy of SHPT in hemodialysis patients, is its primary benefit. The company keeps looking for other needs and possible treatments for people with ESKD in addition to upacicalcet.
Read also- Hong Kong-Based Enteligent has Secured $6 Million in Funding
Pathalys began upacicalcet phase 3 studies for SHPT in May with two identical 375-person trials. Patients on hemodialysis frequently experience this common, although dangerous, side effect of chronic renal disease.
Read also- Israel-Based DreaMed Diabetes has Secured $3 Million in Funding
According to Pathalys earlier this year, pacicalcet “performed exceptionally well” in late-stage studies conducted in Japan, where it is already licensed for SHPT.
“Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet,” Pathalys CEO Neal Fowler said. We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys,” Fowler added.
About Pathalys Pharma
Pathalys Pharma, a private, late-stage clinical biopharmaceutical business, develops innovative therapies for late-stage chronic kidney disease (CKD). Pathalys was founded with Catalys Pacific and DaVita to be a multi-asset pharmaceutical firm for end-stage renal disease patients.
